Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Study ID
AALL0932

Cancer Related
Yes

Healthy Volunteers
No

Study Sites

  • UT Southwestern-Other
  • Children’s Medical Center (Dallas, Plano, Southlake)

Contact
Stephanie McGinn
214 456-8588
stephanie.mcginn@childrens.com

Principal Investigator
Tamra Slone, M.D.

Official Title

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Brief Overview


This partially randomized phase III trial studies different combinations of risk-adapted
chemotherapy regimens and their side effects and comparing how well they work in treating
younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or
B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began
(localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving more than one drug (combination chemotherapy), giving the drugs in
different doses, and giving the drugs in different combinations may kill more cancer cells.

Summary


PRIMARY OBJECTIVES:

l. To determine if a maintenance regimen containing weekly oral methotrexate at 40
mg/m^2/week will result in an improved disease free survival (DFS) compared to that
containing weekly oral methotrexate at 20 mg/m^2/week in the average-risk (AR) subset of
patients with standard-risk B-precursor acute lymphoblastic leukemia (ALL).

II. To determine whether a reduced-pulses maintenance regimen with vincristine (vincristine
sulfate)/dexamethasone pulses delivered every 12 weeks can be used without adversely
impacting DFS as compared to pulses given every 4 weeks in the AR subset of patients with
standard risk B-precursor ALL.

III. To confirm that patients in the low-risk (LR) subset of standard risk B-precursor ALL,
based on clinical and cytogenetic features and minimal residual disease (MRD) criteria, can
attain a 5 year DFS of at least 95% with either a P9904 based regimen that includes 6
courses of intermediate dose (1 g/m^2 over 24 hours) methotrexate without alkylating agents
or anthracyclines (Arm LR-M), or an outpatient based regimen identical to that of AR
patients with reduced vincristine/dexamethasone pulses at 12 week intervals during
maintenance (Arm LR-C).

IV. To provide standardized treatment and enhanced supportive care to children with
standard-risk (SR) Down syndrome-ALL in order to improve outcomes and facilitate further
study of this biologically and clinically unique patient subgroup.

V. To improve understanding of the biology of localized B-lineage lymphoblastic lymphoma
(B-LLy) and Down syndrome (DS) B-LLy by obtaining biologic data, including fluorescence in
situ hybridization (FISH) for recurrent cytogenetic lesions on paraffin specimen, and
banking tissue for future research.

VI. To describe the 5-year EFS and overall survival (OS) of patients with Murphy stage I and
II B-LLy receiving modified AR B-ALL therapy.

SECONDARY OBJECTIVES:

I. To assess the burden of AR B-ALL therapy as measured by surveys of the child's quality of
life, missed days of school/daycare/work by children and parents, family functioning,
parental perception of the child's health vulnerability, physical functioning, and emotional
distress, 1) overall at different time points during and at the end of therapy, and by 2)
comparing children randomized to every 4 week vs. every 12 week dexamethasone/vincristine
pulses during maintenance. (Closed to accrual as of April 19, 2013) II. To characterize the
onset, severity, and natural history of vincristine associated neuropathy by physical
therapists (or occupational therapists) in children undergoing therapy for AR B-ALL, 1)
overall at different time points during and at the end of therapy, and by 2) comparing
children randomized to every 4 week vs. every 12 week dexamethasone/vincristine pulses
during maintenance. (Closed to accrual as of March 15, 2013)

TERTIARY OBJECTIVES:

I. To explore the correlation of minimal marrow disease (MMD) at diagnosis and outcome for
patients with B-LLy.

OUTLINE:

All patients receive induction therapy comprising intrathecal (IT) cytarabine on day 1;
vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) or IV twice daily
(BID) on days 1-28; pegaspargase IV over 1-2 hours on day 4; and IT methotrexate* on days 8
and 29. Patients with Philadelphia chromosome-positive disease are eligible to transfer to
COG-AALL0622 by day 15 of induction therapy and patients with high-risk (HR) or very
high-risk (VHR) disease are eligible to transfer to a COG HR or VHR trial at the end of
induction therapy. Patients with standard-risk disease with Down syndrome (DS) who have bone
marrow minimal residual disease 0.01% are eligible to transfer to the DS stratum of the HR
trial. Patients with induction failure (defined as M3 [> 25% lymphoblasts] on day 29) may be
eligible for the COG VHR-acute lymphoblastic leukemia study.

NOTE: *Patients with DS also receive oral leucovorin calcium every 12 hours on days 10-11
and 31-32.

STANDARD-RISK WITH DOWN SYNDROME:

Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on day 1;
mercaptopurine PO on days 1-28; IT methotrexate on days 1, 8, and 15; and leucovorin calcium
PO every 12 hours on days 3-4, 10-11, and 17-18. Interim maintenance I therapy (8 weeks):
Patients receive vincristine sulfate IV and methotrexate IV over 2-15 minutes on days 1, 11,
21, 31, and 41; IT methotrexate on day 31; and leucovorin calcium PO every 12 hours on days
36-34. Delayed-intensification therapy (8 weeks): Patients receive dexamethasone PO or IV
BID on days 1-7 and 15-21; vincristine sulfate IV and doxorubicin hydrochloride IV over 1-15
minutes on days 1, 8, and 15; pegaspargase IV over 1-2 hours on day 4; cyclophosphamide IV
over 30-60 minutes on day 29; thioguanine PO on days 29-42; cytarabine IV over 1-15 minutes
or subcutaneously (SC) on days 29-32 and 33-39; IT methotrexate on days 1 and 29; and
leucovorin calcium PO every 12 hours on days 3-4 and 31-32. Interim maintenance II therapy
(8 weeks): Patients receive vincristine sulfate IV and methotrexate IV over 2-15 minutes on
days 1, 11, 21, 31, and 41; IT methotrexate on days 1 and 31; and leucovorin calcium PO
every 12 hours on days 3-4 and 33-34. Maintenance therapy: Patients receive vincristine
sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22,
29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on
day 1. Courses repeat every 12 weeks for 2 years (timed from the start of interim
maintenance I therapy).

AVERAGE-RISK:

Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on day 1;
mercaptopurine PO on days 1-28; and IT methotrexate on days 1, 8, and 15.Interim maintenance
I therapy (8 weeks): Patients receive vincristine sulfate IV and methotrexate IV over 2-15
minutes on days 1, 11, 21, 31, and 41 and IT methotrexate on day 31. Delayed intensification
therapy (8 weeks): Patients receive dexamethasone PO or IV BID on days 1-7 and 15-21;
vincristine sulfate IV and doxorubicin hydrochloride IV over 1-15 minutes on days 1, 8, and
15; pegaspargase IV over 1-2 hours on day 4; cyclophosphamide IV over 30-60 minutes on day
29; thioguanine PO on days 29-42; cytarabine IV over 15-30 minutes or SC on days 29-32 and
36-39; and IT methotrexate on days 1 and 29. Interim maintenance II therapy (8 weeks):
Patients receive vincristine sulfate IV and methotrexate IV over 2-15 minutes on days 1, 11,
21, 31, and 41 and IT methotrexate on days 1 and 31. Maintenance therapy: Patients are
randomized to 1 of 4 maintenance therapy treatment arms.

Arm A: Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID
on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64,
71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.

Arm B: Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID
on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43,
50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.

Arm C: Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5;
methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on
days 1-84; and IT methotrexate on day 1.

Arm D: Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5;
higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78;
mercaptopurine PO on days 1-84; and IT methotrexate on day 1.

In all arms, maintenance therapy courses repeat every 12 weeks for 2 years for girls and for
3 years for boys (timed from the start of interim maintenance I therapy).

LOW-RISK: Patients are randomized to 1 of 2 treatment arms.

Arm I (LR-M): Consolidation therapy (19 weeks): Beginning one week after completion of
induction therapy, patients receive vincristine sulfate IV on days 15, 22, 78, and 85;
methotrexate IV over 24 hours and IT methotrexate on days 8, 29, 50, 71, 92, and 113;
leucovorin calcium PO or IV on days 9-10, 30-31, 51-52, 72-73, 93-94, and 114-115;
dexamethasone PO BID or IV on days 15-21 and 78-84; and PO mercaptopurine on days
1-133.Maintenance therapy: Patients receive vincristine sulfate IV on days 1 and 8;
dexamethasone PO BID on days 1-7; methotrexate* PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57,
64, 71, 78, 85, 92, 99, and 106; and mercaptopurine PO on days 1-112. Courses repeat every
16 weeks. Patients also receive IT methotrexate on days 1 and 85 (courses 1 and 4), day 57
(courses 2 and 5), or day 29 (courses 3 and 6). Patients then receive course 7 comprising
vincristine sulfate IV on days 1 and 8; dexamethasone PO BID on days 1-7; methotrexate PO on
days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64; and mercaptopurine PO on days 1-70. Treatment
continues for 2 and ½ years (timed from the date of diagnosis).NOTE: *Patients do not
receive methotrexate PO on the days that they receive IT methotrexate.

Arm II (LR-C): Consolidation therapy (4 weeks): Patients receive vincristine sulfate IV on
day 1; oral mercaptopurine on days 1-28; and IT methotrexate on days 1, 8, and 15. Interim
maintenance I therapy (8 weeks): Patients receive vincristine sulfate IV and methotrexate IV
over 2-15 minutes on days 1, 11, 21, 31, and 41 and IT methotrexate on day 31.
Delayed-intensification therapy (8 weeks): Patients receive dexamethasone PO or IV BID on
days 1-7 and 15-21; vincristine sulfate IV and doxorubicin hydrochloride IV over 1-15
minutes on days 1, 8, and 15; pegaspargase IV over 1-2 hours on day 4; cyclophosphamide IV
over 30-60 minutes on day 29; thioguanine PO on days 29-42; cytarabine IV over 1-15 minutes
or SC on days 29-32 and 36-39; and IT methotrexate on days 1 and 29.Interim maintenance II
therapy (8 weeks): Patients receive vincristine sulfate IV and methotrexate IV over 2-15
minutes on days 1, 11, 21, 31, and 41 and IT methotrexate on days 1 and 31. Maintenance
therapy: Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5;
methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on
days 1-84; and IT methotrexate on day 1. Courses repeat every 12 weeks for 2 years for girls
and for 3 years for boys (timed from the start of interim maintenance I therapy).

After completion of study treatment, patients are followed up periodically for 10 years.

Participant Eligibility


Inclusion Criteria:

- B-ALL patients must be enrolled on AALL08B1 prior to treatment and enrollment on
AALL0932

- Note: B-LLy patients are not eligible for AALL08B1, and can enroll directly onto
AALL0932

- B-ALL patients must have an initial white blood cell count < 50,000/uL

- Patients must have newly diagnosed National Cancer Institute (NCI) Standard Risk
B-ALL or B-LLy Murphy stages I or II; patients with Down syndrome are also eligible

- Note: for B-LLy patients with tissue available for flow cytometry, the criterion
for diagnosis should be analogous to B-ALL; for tissue processed by other means
(i.e. paraffin blocks), the methodology and criteria for immunophenotypic
analysis to establish the diagnosis of B-LLy defined by the submitting
institution will be accepted

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met

Exclusion Criteria:

- With the exception of steroid pretreatment (defined below) or the administration of
intrathecal cytarabine, patients must not have received any prior cytotoxic
chemotherapy for either the current diagnosis of B-ALL or B-LLy or for any cancer
diagnosed prior to initiation of protocol therapy on AALL0932

- Patients receiving prior steroid therapy may be eligible for AALL0932

- Patients with central nervous system 3 (CNS3) leukemia

- CNS status must be known prior to enrollment; (Note: the CNS status must be
determined based on a sample obtained prior to administration of any systemic or
intrathecal chemotherapy, except for steroid pretreatment); B-LLy patients with
CNS3 disease are not eligible for this protocol or the COG HR ALL protocol; it
is recommended that intrathecal cytarabine be administered at the time of the
diagnostic lumbar puncture; this is usually done at the time of the diagnostic
bone marrow or venous line placement to avoid a second lumbar puncture; this is
allowed prior to registration; systemic chemotherapy must begin within 72 hours
of the first dose of intrathecal therapy

- B-ALL patients with testicular leukemia are not eligible for AALL0932

- For B-LLy patients the following additional exclusion criteria apply:

- T-lymphoblastic lymphoma

- Morphologically unclassifiable lymphoma

- Absence of both B-cell and T-cell phenotype markers in a case submitted as
lymphoblastic lymphoma

- CNS3-positive disease or testicular involvement

- M2 (5% - 25% blasts) or M3 (> 25% blasts) marrow

- Female patients who are pregnant are ineligible

- Lactating females are not eligible unless they have agreed not to breastfeed
their infants

- Female patients of childbearing potential are not eligible unless a negative
pregnancy test result has been obtained

- Sexually active patients of reproductive potential are not eligible unless they
have agreed to use an effective contraceptive method for the duration of their
study participation